MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018
Increased focus where we can create the most valueJuly – SeptemberSignificant events during the quarter · Positive top-line joint structure outcomes were reported from the MIV-711 osteoarthritis phase II extension study (MIV-711-202). Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area growth and prevention of cartilage degradation. · The first patient was enrolled and dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with basal cell carcinoma (BCC). · Dr. Linda Basse was